THE EFFECT OF HUMANIZED ANTIBODIES TO ANGPTL4 ON TRIGLYERIDES & VLDL-LEVELS

该子项目是利用资源的许多研究子项目之一 由NIH/NCRR资助的中心赠款提供。次级项目的主要支助 子项目的主要研究者可能是由其他来源提供的， 包括其他NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 高水平的甘油三酯和极低密度脂蛋白（也称为血脂异常）被广泛认为是冠心病和糖尿病发展的主要危险因素。该研究测试了人源化ANGPTL 4抗体通过激活脂蛋白脂肪酶来增加甘油三酯清除率的能力。 在这项原理研究的证明中，我们确定了这些抗体是否可以有效地降低甘油三酯和VLDL并改善肥胖非人灵长类动物的葡萄糖稳态。 这些研究将在未来扩展，以研究长期治疗和其他终点的研究（即，免疫功能的改善），这将导致一个可降解的文件。这些研究使用来自肥胖NHP资源的动物。 进展：这些研究已经完成。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. High levels of triglycerides and VLDL (also known as dyslipidemia) are widely accepted to be a major risk factor in the development of coronary heart disease and diabetes. This study tested the ability humanized ANGPTL4 antibodies to increase triglyceride clearance through activation of the lipoprotein lipase enzyme. In this proof of principle study we determined whether these antibodies can effectively reduce triglycerides and VLDL and improve glucose homeostasis in obese nonhuman primates. These studies will be expanded in the future to investigate prolonged treatment and investigation of other endpoints (i.e., improvement in immune function) that will lead to a publishable paper. These studies used animals from the Obese NHP Resource. Progress: These studies have been completed.